证券代码：688310 证券简称：迈得医疗 迈得医疗工业设备股份有限公司投资者关系活动记录表 2021 年度业绩说明会 编号：2022-002 | --- | --- | --- | |-------------------------|-------------------------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | 业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 通过线上方式参与公司 | 2021 年度业绩说明会的投资者 | | | | | | 时间 | 2022 年 5 月 18 日 | 13:00-14:30 | | 地点 | 上海证券交易所上证路演中心 （网址： | http://roadshow.sseinfo.com/ ） | | 上市公司接 ...

证券代码：688310 证券简称：迈得医疗 迈得医疗工业设备股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |------------------|-----------------------------------------------------------------|--------------------------------------------------| | | | | | 投资者关系活动类 | | 特定对象调研 □分析师会议 | | 别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 □路演活动 | | | | 现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及人 | | | | | 员姓名 前海开源基金：黄智然； 高毅资产：罗鸣； 方正证券：曹佳琳 | | | | | | | | | | | 时间 2022 | 年 6 月 17 日 | 10:00-11:00 | | 地点 迈得医疗 | | | | | | | | 上市公司接待人员 | | 董事、副总经理、董事会秘书：林栋先生 | ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥64,235,359.54, representing a decrease of 0.09% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was ¥8,714,789.59, down 43.99% year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,874,601.72, a decline of 65.26% compared to the previous year[5] - The net profit attributable to shareholders for the year-to-date period was ¥19,287,694.66, down 50.89% year-over-year[5] - Net profit for the third quarter of 2022 was ¥19,924,085.82, a decrease from ¥38,823,970.51 in the same quarter of 2021, reflecting a decline of approximately 48.7%[21] - The total comprehensive income for Q3 2022 was CNY 20,053,137.13, compared to CNY 39,139,532.56 in Q3 2021, reflecting a decrease of approximately 48.8%[22] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.23, down from CNY 0.47 in Q3 2021, representing a decline of 51.1%[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥983,424,301.28, an increase of 11.84% from the end of the previous year[6] - The company's total assets as of the end of the third quarter of 2022 amounted to ¥983,424,301.28, compared to ¥879,311,660.19 at the end of the same period in 2021, showing an increase of about 11.85%[19] - Total liabilities increased to ¥217,211,868.47 in the third quarter of 2022 from ¥116,670,640.13 in the same quarter of 2021, marking an increase of approximately 86.1%[18] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥40,175,806.98, reflecting an increase of 83.26% compared to the previous year[6] - Net cash flow from operating activities for the first three quarters of 2022 was CNY 40,175,806.98, an increase of 83.2% compared to CNY 21,922,778.27 in the same period of 2021[26] - The net increase in cash and cash equivalents for Q3 2022 was -CNY 28,669,436.43, compared to -CNY 95,113,060.16 in Q3 2021, indicating an improvement in cash flow management[27] - The cash and cash equivalents balance at the end of Q3 2022 was CNY 286,172,215.95, down from CNY 330,348,840.49 at the end of Q3 2021[27] Research and Development - Research and development expenses for Q3 2022 amounted to ¥8,290,060.01, a decrease of 11.90% year-over-year[6] - Research and development expenses for the first three quarters of 2022 were ¥26,912,034.42, up from ¥22,330,472.31 in 2021, indicating an increase of approximately 20.4%[20] Shareholder Information - The top shareholder, Lin Junhua, holds 39,986,000 shares, representing 47.83% of the total shares, indicating a strong control over the company[12] - The second-largest shareholder, Chen Wanshun, owns 12,630,000 shares, accounting for 15.11% of the total shares[12] - The company’s total number of ordinary shares outstanding at the end of the reporting period was 3,997,000[12] Strategic Initiatives - The company is actively engaging in market expansion and product development as part of its strategic initiatives[14] - The company has approved the grant of reserved restricted stock to incentive objects as part of its stock incentive plan, indicating a focus on employee retention and motivation[14] - The company has initiated a stock incentive plan adjustment, which may impact future stock performance and employee engagement[15] - The company has not reported any significant changes in its debt structure or major acquisitions during the reporting period[14] Other Financial Metrics - Basic earnings per share for Q3 2022 were ¥0.10, down 47.37% from the same period last year[6] - The weighted average return on equity was 1.15%, a decrease of 0.99 percentage points compared to the previous year[6] - The company reported a total of ¥3,840,187.87 in non-recurring gains for the current period[10] - Accounts receivable increased to ¥123,151,856.49 from ¥115,080,615.46, reflecting a growth of about 7.5% year-over-year[16] - The company’s financing receivables rose significantly to ¥49,868,651.46 from ¥16,603,117.44, marking an increase of approximately 200%[16] - The company reported a decrease in tax refunds received, amounting to CNY 8,901,480.61 in Q3 2022, down from CNY 12,499,434.35 in Q3 2021[26]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[13] - The company has set a revenue guidance of RMB 1.2 billion for the full year 2022, reflecting an expected growth of 10% compared to 2021[13] - The company's operating revenue for the first half of 2022 was approximately ¥133.22 million, representing a 3.27% increase compared to ¥129.01 million in the same period last year[19] - Net profit attributable to shareholders decreased by 55.42% to approximately ¥10.57 million from ¥23.72 million year-on-year[19] - The basic earnings per share dropped by 53.57% to ¥0.13 from ¥0.28 in the previous year[19] - The net cash flow from operating activities decreased by 44.29% to approximately ¥16.06 million from ¥28.83 million year-on-year[20] - The net profit attributable to shareholders was 10.57 million yuan, with a net profit of 7.68 million yuan after deducting non-recurring gains and losses[108] - The company achieved operating revenue of 133.22 million yuan, a year-on-year increase of 3.27%[121] Research and Development - The company has invested RMB 50 million in R&D for new technologies aimed at improving product efficiency and safety[13] - Research and development expenses accounted for 13.98% of operating revenue, an increase of 3.96 percentage points compared to 10.02% in the same period last year[19] - R&D expenses increased by 44.12% year-over-year, totaling ¥186,219,744.41, driven by increased direct material costs and R&D salaries[86] - The company has submitted 72 new patent applications during the reporting period, including 35 invention patents, and has received 66 new patent grants, with a total of 304 patents granted by the end of the reporting period[43] - The company has a strong R&D team of 111 personnel, with an average salary of 7.20 million RMB, representing 18.38% of the total workforce[99] - The company holds 156 invention patents, 146 utility model patents, and 43 software copyrights, showcasing its leading R&D capabilities in the domestic industry[100] Market Expansion and Strategy - User data indicates a growth in the customer base by 20%, reaching a total of 1 million active users[13] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by the end of 2023[13] - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance the company's production capacity by 40%[13] - The company specializes in the research, production, and sales of medical consumables automation equipment, focusing on automated assembly, cutting, and online testing of medical consumables[25] - The company has established long-term cooperative relationships with well-known medical consumables manufacturers, enhancing its market position[106] Product Development and Innovation - New product development includes the launch of a pre-filled syringe, which is expected to capture a 25% market share in its category within the next year[13] - The company has developed several intelligent control system software versions for various medical equipment, enhancing automation capabilities[28] - The company has achieved significant advancements in automated production technologies for dialysis devices, reducing the risk of contamination and adverse reactions in patients[79] - The company has developed a new packaging method for infusion devices, utilizing a ring-shaped bagging approach to meet diverse market demands[82] - The company has implemented a GMP data management platform that ensures data integrity and compliance with regulatory requirements[80] Financial Risks and Challenges - The company has identified potential risks related to supply chain disruptions, which may impact future performance[13] - The company faces risks related to the potential inability to generate timely benefits from R&D investments, which could reduce current profits[113] - The company is exposed to risks from the loss of key technical personnel and potential technology leaks due to increasing industry competition[113] - The company has a risk of declining gross profit margins due to rising labor costs and competitive pricing strategies from rivals[114] - The company is at risk of not being able to fulfill major contracts, which could adversely affect future operating performance[117] Sustainability and Compliance - The management emphasizes a commitment to sustainability, with plans to reduce carbon emissions by 20% over the next three years[13] - The company is not classified as a key pollutant discharge unit and does not face any administrative penalties related to environmental issues[148] - The company reported compliance with environmental protection laws, with no pollution incidents or penalties during the reporting period[149] - The company implemented measures to reduce carbon emissions through technological innovation and process optimization, enhancing operational efficiency[151] Corporate Governance and Shareholder Relations - The company has committed not to transfer or repurchase shares held prior to the IPO for 36 months from the date of listing[157] - The company plans to implement a share buyback plan if the stock price triggers the conditions, with a minimum funding of 5% of the previous year's audited net profit[163] - The company has established a profit distribution policy approved at the 2018 annual general meeting, detailing the dividend return plan for the next three years (2019-2021)[178] - The company will ensure that any compensation system established by the board or compensation committee is linked to the execution of return measures[176] - The company will take legal responsibility for the authenticity, accuracy, completeness, and timeliness of the prospectus, and will compensate investors for losses caused by any misleading statements[180]

Financial Performance - The company's operating revenue for Q1 2022 was ¥51,996,527.67, representing a year-on-year increase of 10.93%[5] - The net profit attributable to shareholders decreased by 74.63% to ¥2,404,739.46 compared to the same period last year[5] - The net cash flow from operating activities was negative at -¥24,301,778.02, a decline of 253.51% year-on-year[5] - Total operating revenue for Q1 2022 was ¥51,996,527.67, an increase of 11.5% compared to ¥46,873,165.03 in Q1 2021[20] - Net profit for Q1 2022 was ¥2,205,325.56, a decrease of 76.5% from ¥9,354,043.72 in Q1 2021[21] - The company's gross profit margin decreased to 1.0% in Q1 2022 from 10.5% in Q1 2021[20] - The company reported a decrease in comprehensive income to ¥2,302,934.96 in Q1 2022, down from ¥9,545,941.81 in Q1 2021[21] Expenses and Investments - Research and development expenses totaled ¥8,748,981.09, an increase of 39.19% from the previous year, accounting for 16.83% of operating revenue, up by 3.42 percentage points[6] - The company reported a significant increase in management and R&D expenses, which outpaced revenue growth, leading to a substantial decline in net profit[8] - Research and development expenses increased to ¥8,748,981.09 in Q1 2022, compared to ¥6,285,834.86 in Q1 2021, marking an increase of 39.2%[20] - The company has invested CNY 10.41 million in Weigao Automation, acquiring 51% equity stake[12] Assets and Liabilities - The total assets at the end of the reporting period were ¥864,866,773.36, a decrease of 1.64% from the end of the previous year[6] - As of March 31, 2022, total assets amounted to CNY 864.87 million, a decrease from CNY 879.31 million as of December 31, 2021[17] - The total liabilities as of Q1 2022 were ¥95,630,201.56, a decrease from ¥116,670,640.13 in the previous year[18] - The total equity attributable to shareholders increased to ¥771,131,925.96 in Q1 2022 from ¥764,363,990.00 in Q1 2021[18] Cash Flow - Cash inflow from operating activities totaled $37,736,410.50, a decrease from $82,340,572.70 in the previous year, reflecting a decline of approximately 54.1%[24] - Net cash outflow from operating activities was $24,301,778.02, compared to a net inflow of $15,830,900.40 in the same period last year[24] - Cash inflow from investment activities amounted to $70,195,000.00, with a net cash outflow of $11,227,276.47, indicating a significant investment strategy[24] - Total cash outflow for purchasing fixed assets and other long-term assets was $26,422,276.47, up from $21,623,300.11 in the previous year[24] - Cash flow from financing activities resulted in a net outflow of $397,258.25, with no cash inflow recorded[25] - The ending balance of cash and cash equivalents was $278,858,739.67, down from $419,547,478.23 at the end of the previous year, reflecting a decrease of approximately 33.5%[25] - The company reported a significant increase in cash paid to employees, totaling $24,658,292.92, compared to $21,793,363.82 in the previous year, representing an increase of about 13.5%[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,476[10] - The largest shareholder, Lin Junhua, holds 39,986,000 shares, accounting for 47.83% of the total shares[10] Strategic Partnerships - The company has established a strategic partnership with Weigao Group, indicating a focus on market expansion in medical consumables[12] - The company has recognized Weigao Group as a related party due to the recent investment, impacting future transactions[14] Accounting Standards - The company is implementing new accounting standards starting in 2022, which may impact future financial reporting and analysis[25]

Financial Performance - The company plans to distribute a cash dividend of RMB 3.8 per 10 shares (including tax) for the 2021 fiscal year[5]. - The company has not achieved profitability since its listing[4]. - The company's operating revenue for 2021 was CNY 315,525,810.78, representing a 19.90% increase compared to CNY 263,168,423.81 in 2020[21]. - The net profit attributable to shareholders for 2021 was CNY 64,479,103.03, a 9.15% increase from CNY 59,071,883.19 in 2020[21]. - The company's cash flow from operating activities for 2021 was CNY 84,886,101.10, reflecting a 21.11% increase from CNY 70,090,863.66 in 2020[21]. - The total assets at the end of 2021 were CNY 879,311,660.19, a 7.76% increase from CNY 816,012,786.32 at the end of 2020[21]. - The net assets attributable to shareholders at the end of 2021 were CNY 764,363,990.00, a 3.72% increase from CNY 736,960,222.79 at the end of 2020[21]. - The weighted average return on equity for 2021 was 8.64%, an increase of 0.43 percentage points from 8.21% in 2020[22]. - The gross margin decreased from 53.01% in 2020 to 50.12% in 2021, primarily due to the decline in high-margin mask machine sales[119]. Research and Development - Research and development expenses increased by CNY 12,224,300, impacting the net profit growth rate[23]. - The company invested 12.19% of its operating revenue in R&D in 2021, up from 9.97% in 2020[22]. - The company submitted 61 new patent applications during the reporting period, including 21 invention patents, and received 7 new patent grants[34]. - The company has a total of 239 granted patents, including 155 invention patents, and 38 software copyrights[34]. - The company has established a research institute and technology center, focusing on the development of various automated medical assembly equipment[57]. - The company has developed multiple products that have overcome key technical challenges, achieving domestic firsts and replacing imports, filling gaps in the domestic market[37]. - The company has formed a comprehensive R&D system integrating eight major modules, reflecting its commitment to high-tech industry development[91]. - The company is in the development phase for several new products, including a pre-filled syringe automatic injection pen production line, which aims to enhance automation and reduce costs for manufacturers[101]. Market Trends and Opportunities - The intelligent manufacturing equipment market in China is projected to exceed 2.6 trillion yuan by 2022, indicating significant market potential[49]. - The medical consumables industry is expected to maintain rapid growth due to factors such as the aging population, increased healthcare spending, and comprehensive insurance coverage in China[50]. - The global medical device industry reached a market size of $49.35 billion in 2020, with a year-on-year growth of 8.96%[61]. - China's medical device market size was approximately 772.1 billion yuan in 2020, reflecting a year-on-year increase of 21.76%[62]. - The demand for intelligent production equipment is increasing among domestic medical consumables manufacturers due to stricter government regulations and rising labor costs[51]. - The company is exploring new markets in orthopedic and drug-device combination fields, indicating a focus on diversification[115]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures for external guarantees[8]. - The company has not reported any instances where more than half of the directors could not guarantee the authenticity, accuracy, and completeness of the annual report[8]. - The company emphasizes transparency in information disclosure, ensuring timely and accurate reporting of significant information[174]. - The company is committed to enhancing investor relations and protecting the rights of minority shareholders, in accordance with relevant laws and regulations[167]. - The company has established a comprehensive governance system, including rules for shareholder meetings, board meetings, and supervisory meetings[172]. Operational Efficiency and Challenges - The company employs an order-based production model, ensuring production aligns with customer contracts and technical specifications[44]. - The company faces risks related to rapid technological updates and the need for continuous innovation in the medical consumables sector[114]. - The company anticipates potential adverse impacts on future performance due to ongoing global pandemic conditions[126]. - The company has agreed to terminate a contract with ARSMED, involving a sales amount of 2.43 million USD, due to non-compliance by the client[122]. - The company has established a supplier assessment system to ensure quality and efficiency in procurement processes[43]. Strategic Initiatives and Future Plans - The company plans to continue focusing on technological innovation and process improvement to meet market demands[23]. - The company aims to enhance its production and R&D capabilities through fundraising projects, with completion expected by December 31, 2022[162]. - The company intends to expand its market presence in Europe, the Americas, and developing countries to increase market penetration and share[165]. - The company will strengthen brand building to enhance brand influence and create brand premium[166]. - The company plans to modify and resell equipment previously produced for ARSMED, expecting a net realizable value higher than the cost[122]. Human Resources and Management - The total number of employees at the parent company is 480, with 78 employees at major subsidiaries, totaling 558 employees[200]. - The company aims to build a learning organization and service-oriented enterprise, focusing on talent development and retention[168]. - The average salary for R&D personnel increased to 14.20 million RMB, compared to 12.70 million RMB in the previous year[104]. - The company has established a remuneration and assessment committee to review and approve the remuneration policies for directors and senior management[187]. - The management team includes individuals with extensive experience in finance, engineering, and technology, enhancing the company's operational capabilities[180].

Revenue and Profit - Revenue for Q3 2021 reached ¥64,290,077.42, an increase of 28.69% compared to the same period last year[4] - Net profit attributable to shareholders was ¥15,558,095.61, up 49.92% year-on-year[4] - Net profit excluding non-recurring gains and losses was ¥14,032,644.40, a 42.77% increase from the previous year[4] - Basic earnings per share for the period was ¥0.19, reflecting a 58.33% increase compared to the same period last year[5] - Total operating revenue for the first three quarters of 2021 reached ¥193,295,941.21, an increase of 17.7% compared to ¥164,290,395.12 in the same period of 2020[21] - Net profit for the first three quarters of 2021 was ¥38,823,970.51, a decrease of 24.4% from ¥51,310,892.84 in the same period of 2020[22] - Earnings per share for the first three quarters of 2021 were ¥0.47, down from ¥0.62 in the previous year[23] Research and Development - Total R&D investment amounted to ¥9,409,684.39, representing a 44.77% increase year-on-year[5] - R&D expenses accounted for 14.64% of revenue, an increase of 1.63 percentage points compared to the previous year[5] - Research and development expenses for the first three quarters of 2021 amounted to ¥22,330,472.31, an increase from ¥19,541,128.25 in the previous year[21] Cash Flow and Assets - Cash flow from operating activities for the year-to-date was ¥21,922,778.27, down 51.36% compared to the previous year[4] - The company's cash and cash equivalents decreased from 425,461,900.65 RMB at the end of 2020 to 330,348,840.49 RMB by September 30, 2021, a decline of approximately 22.3%[15] - Total current assets amounted to 601,404,589.70 RMB, down from 664,895,499.16 RMB year-over-year[17] - Non-current assets increased from 151,117,287.16 RMB to 214,829,498.76 RMB, reflecting a growth of approximately 42%[17] - The total assets of the company were reported at 816,234,088.46 RMB, slightly up from 816,012,786.32 RMB at the end of 2020[17] - The total liabilities as of the end of the third quarter of 2021 were ¥83,171,755.42, compared to ¥80,289,985.84 at the end of the previous year[18] - Total equity attributable to shareholders was ¥734,752,080.43, slightly down from ¥736,960,222.79 in the previous year[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 2,748[11] - The top shareholder, Lin Junhua, holds 39,986,000 shares, representing 47.83% of total shares[11] Inventory and Costs - The company reported a significant increase in inventory from 101,936,175.45 RMB to 121,988,401.13 RMB, indicating a rise of approximately 19.6%[15] - Total operating costs for the first three quarters of 2021 were ¥164,318,501.66, up 45.1% from ¥113,068,088.95 in the previous year[21] Financial Activities - The company plans to implement a stock incentive plan as approved in the board meetings held in September and October 2021[13] - The company has engaged in strategic placements, with Guangfa Qianhe Investment Co., Ltd. participating in the IPO with a subscription of 1,045,000 shares, accounting for 5% of the total issuance[12] - The company reported a financial income of ¥3,614,170.86 for the first three quarters of 2021, compared to ¥7,615,187.03 in the same period of 2020[21] Cash Flow from Activities - The net cash flow from operating activities was $21,922,778.27, a decrease of 51.2% compared to $45,067,757.03 in the previous year[26] - Total cash outflow from operating activities amounted to $184,058,633.84, up from $173,070,312.10 year-over-year[26] - The net cash flow from investing activities was -$74,003,278.82, compared to $325,008,603.52 in the same period last year, indicating a significant decline[26] - The net cash flow from financing activities was -$42,811,848.24, compared to -$58,089,505.67 in the previous year, showing an improvement[27] - The total cash and cash equivalents at the end of the period were $330,348,840.49, down from $423,656,014.66 year-over-year[27] - The company paid $41,800,000.00 in dividends and interest, an increase from $29,439,505.67 in the previous year[27] - The cash outflow from financing activities was $42,811,848.24, compared to $58,089,505.67 in the same period last year[27] - The impact of exchange rate changes on cash and cash equivalents was -$220,711.37, contrasting with a positive impact of $16,273.89 in the previous year[27] - The company reported a significant increase in cash outflow related to employee payments, totaling $58,675,709.68, compared to $43,397,854.19 last year[26] Margin and Product Mix - The company experienced a decline in gross margin due to a shift in product mix, with lower margins from customized products compared to last year's higher-margin products[9]

Financial Performance - The company reported a revenue of RMB 200 million for the first half of 2021, representing a year-on-year increase of 15%[15]. - The company's operating revenue for the first half of the year was approximately CNY 129 million, representing a 12.83% increase compared to the same period last year[24]. - Net profit attributable to shareholders decreased by 42.98% to approximately CNY 23.72 million, while the net profit excluding non-recurring gains and losses fell by 49.52% to approximately CNY 19.39 million[23]. - Basic and diluted earnings per share both decreased by 44% to CNY 0.28, and the basic earnings per share excluding non-recurring gains and losses dropped by 50% to CNY 0.23[22]. - The weighted average return on equity decreased by 2.56 percentage points to 3.23%[22]. - The total profit reached 28.64 million yuan, with a net profit attributable to shareholders of 23.72 million yuan, and a net profit of 19.39 million yuan after deducting non-recurring gains and losses[99]. - The company achieved a sales revenue of 263.17 million yuan in 2020, marking a year-on-year increase of 25.5% compared to 2019[48]. Research and Development - The company has allocated RMB 30 million for R&D in advanced medical equipment technologies for the upcoming fiscal year[15]. - Research and development expenses accounted for 10.02% of operating revenue, down from 11.41% in the previous year[22]. - The company has developed several products that have overcome key technical challenges, achieving domestic firsts and replacing imports[31]. - The company is focused on the research and development of intelligent control system software for medical equipment, including the automatic assembly system control software for medical dialysis devices[32]. - The company has developed software V1.0 for medical hollow fiber spinning line control and optimized the GMP data management platform, enhancing digital transformation for downstream medical consumables manufacturers[33]. - The company has developed 15 core technologies in the field of medical consumables intelligent equipment, with four new technologies added during the reporting period[68]. - The company holds 155 invention patents, 81 utility model patents, and 34 software copyrights as of the end of the reporting period[45]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2023[15]. - The company plans to expand its market presence by enhancing its product offerings in the medical consumables sector, particularly in safety infusion and blood purification equipment[30]. - The company is actively exploring new markets and product lines, including orthopedic and pre-filled syringe equipment, to enhance its competitive edge[107]. - The company is positioned in the "C35 Specialized Equipment Manufacturing" industry, focusing on automation in the production of medical consumables[38]. - The company has established long-term cooperative relationships with well-known medical consumables manufacturers, enhancing its reputation and trust in the industry[96]. Operational Efficiency - The company employs a procurement model that includes centralized purchasing to reduce costs and improve delivery times, with a supplier assessment system in place for quarterly evaluations[34]. - The production model is based on order-driven production, ensuring that production aligns with customer contracts and requirements, thereby maintaining product quality and delivery timelines[35]. - The primary sales method is direct sales, with a focus on understanding customer needs and providing tailored solutions for medical consumables manufacturing[36]. - The company has achieved significant advancements in the assembly technology of soft and adhesive medical consumables, enhancing production efficiency and product quality[71]. - The company has developed automated packaging technologies, including folding box packaging and blister packaging, to meet diverse customer needs[74]. Risk Factors and Compliance - Risk factors include potential regulatory changes that could impact product approvals and market entry strategies[15]. - The company is exposed to foreign exchange risks, with exchange gains of 149,500 yuan and losses of 208,300 yuan reported for 2020 and the first half of 2021, respectively[117]. - The company maintains a strong focus on internal governance and compliance with capital market regulations, ensuring timely and accurate information disclosure[102]. - The company has complied with environmental regulations and did not face any administrative penalties related to environmental issues during the reporting period[143]. Future Outlook - The company has set a performance guidance of 10-15% revenue growth for the second half of 2021[15]. - The market for medical consumables is expected to grow rapidly, driven by factors such as an aging population and increased healthcare spending in China[41]. - The medical device market in China is expected to exceed 900 billion yuan by 2022, maintaining a growth rate of around 20%[49]. - The company is committed to continuous R&D and innovation to keep pace with rapid technological advancements in the medical consumables sector[42]. Corporate Governance and Shareholder Relations - The company has committed to a three-year dividend return plan to enhance shareholder returns and ensure stable profit distribution mechanisms[168]. - The company will not engage in any competitive activities that may harm its business or the rights of its shareholders[189]. - The company will ensure the authenticity, accuracy, completeness, and timeliness of its IPO prospectus, bearing legal responsibility for any misstatements[183]. - The company will publicly explain the reasons for any non-fulfillment of commitments and apologize to investors if such situations arise[178].

Financial Performance - In 2020, the company's operating income increased by 25.59% to CNY 263,168,423.81 compared to 2019 [24]. - The net profit attributable to shareholders rose by 26.35% to CNY 59,071,883.19 in 2020, driven by revenue growth and lower expense growth rates [26]. - The net profit after deducting non-recurring gains increased by 51.32% to CNY 55,626,994.92, reflecting strong operational performance [27]. - The net cash flow from operating activities surged by 395.86% to CNY 70,090,863.66, attributed to improved cash collection and higher interest income from cash management [28]. - The basic earnings per share decreased slightly by 2.74% to CNY 0.71, due to an increase in the weighted average share capital [25]. - The total assets at the end of 2020 were CNY 816,012,786.32, a 1.44% increase from 2019 [24]. - The net assets attributable to shareholders increased by 4.20% to CNY 736,960,222.79 at the end of 2020 [24]. - The company achieved sales of 263.17 million yuan in 2020, marking a growth from 209.55 million yuan in 2019, with a market share ranking first in the industry [54]. - The company achieved operating revenue of 263.17 million RMB, an increase of 25.59% compared to 2019 [134]. - Net profit attributable to shareholders reached 59.07 million RMB, up 26.35% year-on-year [134]. - The company's gross profit margin improved from 48.48% in 2019 to 52.96% in 2020 [120]. Research and Development - The R&D expenditure as a percentage of operating income was 9.97%, showing a slight increase from 9.82% in 2019 [25]. - The company achieved a 27.56% increase in research and development (R&D) expenses, totaling ¥26,234,713.25 compared to ¥20,567,308.97 in the previous year [86]. - R&D expenses accounted for 9.97% of total revenue, up from 9.82% year-over-year, indicating a slight increase in investment relative to revenue [87]. - The company has developed eleven core technologies in the field of medical consumables intelligent equipment, with four new technologies added during the reporting period [75]. - The company has obtained a total of 38 intellectual property rights related to its advanced technologies, including 24 invention patents and 14 utility model patents [76]. - The company has established a transparent production data management platform, enhancing the intelligence and traceability of its manufacturing processes [83]. - The company is actively pursuing new product development and market expansion strategies to enhance its competitive position in the medical consumables sector [76]. Market and Industry Trends - The demand for intelligent production equipment is increasing due to stricter quality requirements and regulatory oversight in the medical consumables sector [47]. - The industry is expected to grow rapidly, driven by factors such as an aging population and increased healthcare spending in China [48]. - The pre-filled syringe market in China is rapidly developing, driven by breakthroughs in domestic technology and the increasing demand for biological drugs [62]. - The biological drug market in China was valued at 262.2 billion yuan in 2018, with expectations to reach 833.2 billion yuan by 2025, reflecting an annual compound growth rate of 18% [64]. - The company is focusing on enhancing innovation and accelerating technological upgrades in response to the volume-based procurement system, which has led to price reductions of 50% or more in some cases [60]. - The company is expected to benefit from the ongoing consolidation in the medical device industry, as non-compliant small enterprises are likely to exit the market, allowing resources to flow to leading companies [60]. Corporate Governance and Shareholder Relations - The company plans to implement a stable and sustainable profit distribution policy, ensuring that cash dividends account for at least 10% of the distributable profits each year, provided there are no major investment plans [178]. - The company emphasizes the importance of brand building as an intangible asset that significantly contributes to business value and aims to meet the increasing demands of customers [169]. - The company will strengthen investor relations management to protect the rights of minority shareholders and enhance communication with investors [171]. - The company is committed to establishing a learning-oriented team culture, encouraging continuous learning and adherence to company regulations among all management levels [172]. - The company will refine its corporate governance structure and decision-making mechanisms to enhance operational efficiency and competitiveness [173]. - The company has committed to not transferring or repurchasing shares for 36 months from the date of its initial public offering [189]. Risk Management - The company has outlined potential risks in its operations and corresponding countermeasures in the report [6]. - The company emphasizes the importance of forward-looking statements and advises investors to be cautious regarding investment risks [8]. - The company faces risks related to potential declines in gross profit margins due to rising labor costs and market saturation [120]. - The company is facing potential risks related to contract fulfillment with ARSMED, with 202 million USD at stake if negotiations fail [127]. - The company’s international business expansion may be impacted by geopolitical tensions and trade sanctions [133]. Product Development and Innovation - The company launched new products, including fully automatic mask machines and melt-blown extrusion machines, in response to the COVID-19 pandemic, positively impacting revenue and profit margins [24]. - The company developed several intelligent control systems for medical equipment, enhancing its product offerings and supporting digital transformation for downstream medical consumables manufacturers [39]. - The company has implemented significant improvements in production processes, resulting in a reduction of defect rates from ≤1%-1.5% to ≤0.0001% for certain products, enhancing overall product quality [102]. - The company has established long-term partnerships with well-known medical consumables manufacturers, enhancing its reputation and trust within the industry [107]. - The company has made advancements in the drying technology for dialysis membranes, ensuring the detection of membrane defects and improving overall product reliability [78]. Dividend Policy - The company plans to distribute a cash dividend of RMB 5 per 10 shares (including tax) for the 2020 fiscal year, pending approval from the annual shareholders' meeting [7]. - In 2020, the company distributed cash dividends totaling RMB 41.8 million, representing 70.76% of the net profit attributable to ordinary shareholders [186]. - The cash dividend per 10 shares in 2020 was RMB 5, compared to RMB 3.5 in 2019 and RMB 8 in 2018 [186]. - The proportion of cash dividends to net profit has shown a consistent trend, with 62.58% in 2019 and 90.13% in 2018 [186].

2021 年第一季度报告 公司代码：688310 公司简称：迈得医疗 迈得医疗工业设备股份有限公司 2021 年第一季度报告 1/20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 9 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 | | | 3/20 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末 增减(%) 总资产 848,667,501.52 816,012,786.32 4.00 归属于上市公司股东 的净资产 746,629,112.14 736,960,222.79 1.31 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) 经营活动产生的现金 流量净额 15,830,900.40 -8,493,133.64 286.40 年初至报告期末 上年初至上年报告期末 比上年同期增减（%） 营业收入 46,873,165.03 22,468,656.63 108.62 归 ...